TABLE 1.

Clinical characteristics of the study participants

SubjectAge (yr)GenderaCD4+ T-cell count (cells/mm3)bDuration of disease (yr)Pretherapy viral load (copies/ml)Vaccine doseRoute of administration
BaselineNadir
125M1,195442567,273Lows.c.
237M81956411503Lowi.v.
345M642311468,100Lows.c.
448M6993507NAcLowi.v.
545F8092411541,552Lows.c.
642M7394915NALowi.v.
732M974340438,058Highi.v.
865F64564101,067,110Highs.c.
948F558591155,031Highi.v.
1047M471468456,759Highs.c.
1143M7443101179,000Highs.c.
1259M5671501310,899Highi.v.
1334M4642361069,171Highi.v.
1441M1,6067236NAHighs.c.
1544M3498392,161,402Highi.v.
1647M646NA19NAHighs.c.
1738M457138200,000Highi.v.
1847M475259567,273Highs.c.
  • a M, male; F, female.

  • b The baseline count was obtained at the time of screening for the protocol. The nadir count is the lowest recorded value for each patient.

  • c NA, not available.